Heterologous ChAdOx1 NCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses Among Health Care Workers

Overview

Journal Vaccines (Basel)

Date 2021 Aug 28

PMID 34451982

Citations 41

Authors

Louise Benning

Maximilian Tollner

Asa Hidmark

Matthias Schaier

Christian Nusshag

Florian Kalble

Paula Reichel

Mirabel Buylaert

Julia Grenz

Gerald Ponath

Katrin Klein

Martin Zeier

Caner Susal

Paul Schnitzler

Christian Morath

Claudius Speer

Affiliations

Soon will be listed here.

Abstract

Despite limited data on safety and immunogenicity, heterologous prime-boost vaccination is currently recommended for individuals with ChAdOx1 nCoV-19 prime immunization in certain age groups. In this prospective, single-center study we included 166 health care workers from Heidelberg University Hospital who received either heterologous ChAdOx1 nCoV-19/BNT162b2, homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination between December 2020 and May 2021. We measured anti-S1 IgG, SARS-CoV-2 specific neutralizing antibodies, and antibodies against different SARS-CoV-2 fragments 0-3 days before and 19-21 days after boost vaccination. Before boost, 55/70 (79%) ChAdOx1 nCoV-19-primed compared with 44/45 (98%) BNT162b2-primed individuals showed positive anti-S1 IgG with a median (IQR) anti-S1 IgG index of 1.95 (1.05-2.99) compared to 9.38 (6.26-17.12). SARS-CoV-2 neutralizing antibodies exceeded the threshold in 24/70 (34%) of ChAdOx1 nCoV-19-primed and 43/45 (96%) of BNT162b2-primed individuals. After boosting dose, median (IQR) anti-S1 IgG index in heterologous ChAdOx1 nCoV-19/BNT162b2 vaccinees was 116.2 (61.84-170), compared to 13.09 (7.03-29.02) in homologous ChAdOx1 nCoV-19 and 145.5 (100-291.1) in homologous BNT162b2 vaccinees. All boosted vaccinees exceeded the threshold for neutralization, irrespective of their vaccination scheme. Vaccination was well-tolerated overall. We show that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals.

Citing Articles

SARS-CoV-2 Immunization Index in the Academic Community: A Retrospective Post-Vaccination Study.

Oliveira K, Almeida A, Silva C, Brito M, Ribeiro E Infect Dis Rep. 2024; 16(6):1084-1097.

PMID: 39728010 PMC: 11675320. DOI: 10.3390/idr16060088.

Factors associated with the worsening of COVID-19 symptoms among cohorts in community- or home-isolation care in southern Thailand.

Sila T, Suriyaamorn W, Toh C, Rajborirug S, Surasombatpattana S, Thongsuksai P Front Public Health. 2024; 12:1350304.

PMID: 38572011 PMC: 10987961. DOI: 10.3389/fpubh.2024.1350304.

Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose.

Sanna G, Marongiu A, Firinu D, Piras C, Palmas V, Galdiero M Clin Exp Med. 2024; 24(1):12.

PMID: 38244064 PMC: 10799790. DOI: 10.1007/s10238-023-01276-x.

A Systematic Evaluation of the SARS-CoV-2 Vaccine-Induced Anti-S-RBD-Ig Response in a Population of Health Care Workers.

Hentschel V, Horsch C, Mayer B, Thies A, Qian W, Kroschel J Vaccines (Basel). 2023; 11(9).

PMID: 37766143 PMC: 10537165. DOI: 10.3390/vaccines11091467.

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021.

Fortunato F, Prato R, Iannelli G, Ascatigno L, Loconsole D, Lopalco P Hum Vaccin Immunother. 2023; 19(1):2209919.

PMID: 37226552 PMC: 10294748. DOI: 10.1080/21645515.2023.2209919.

References

Gross R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D . Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine. 2021; 75:103761. PMC: 8682749. DOI: 10.1016/j.ebiom.2021.103761. View

Muller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R . Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clin Infect Dis. 2021; 73(11):2065-2072. PMC: 8135422. DOI: 10.1093/cid/ciab381. View

Tan C, Chia W, Qin X, Liu P, Chen M, Tiu C . A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020; 38(9):1073-1078. DOI: 10.1038/s41587-020-0631-z. View

Dan J, Mateus J, Kato Y, Hastie K, Yu E, Faliti C . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371(6529). PMC: 7919858. DOI: 10.1126/science.abf4063. View

Speer C, Goth D, Benning L, Buylaert M, Schaier M, Grenz J . Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clin J Am Soc Nephrol. 2021; 16(7):1073-1082. PMC: 8425619. DOI: 10.2215/CJN.03700321. View

Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-1993. PMC: 7674972. DOI: 10.1016/S0140-6736(20)32466-1. View

Greinacher A, Thiele T, Warkentin T, Weisser K, Kyrle P, Eichinger S . Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021; 384(22):2092-2101. PMC: 8095372. DOI: 10.1056/NEJMoa2104840. View

Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C . Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021; 9(11):1255-1265. PMC: 8360702. DOI: 10.1016/S2213-2600(21)00357-X. View

Sattler A, Schrezenmeier E, Weber U, Potekhin A, Bachmann F, Straub-Hohenbleicher H . Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021; 131(14). PMC: 8279581. DOI: 10.1172/JCI150175. View

10.

Bray R, Lee J, Brescia P, Kumar D, Nong T, Shih R . Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins. Transplantation. 2020; 105(1):79-89. DOI: 10.1097/TP.0000000000003524. View

11.

Pritchard E, Matthews P, Stoesser N, Eyre D, Gethings O, Vihta K . Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021; 27(8):1370-1378. PMC: 8363500. DOI: 10.1038/s41591-021-01410-w. View

12.

Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M . Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021; 384(23):2202-2211. PMC: 8112532. DOI: 10.1056/NEJMoa2105385. View

13.

Klein S, Flanagan K . Sex differences in immune responses. Nat Rev Immunol. 2016; 16(10):626-38. DOI: 10.1038/nri.2016.90. View

14.

Krammer F, Srivastava K, Alshammary H, Amoako A, Awawda M, Beach K . Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021; 384(14):1372-1374. PMC: 8008743. DOI: 10.1056/NEJMc2101667. View

15.

Shaw R, Stuart A, Greenland M, Liu X, Nguyen Van-Tam J, Snape M . Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021; 397(10289):2043-2046. PMC: 8115940. DOI: 10.1016/S0140-6736(21)01115-6. View

16.

Schultz N, Sorvoll I, Michelsen A, Munthe L, Lund-Johansen F, Ahlen M . Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021; 384(22):2124-2130. PMC: 8112568. DOI: 10.1056/NEJMoa2104882. View

17.

Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M . Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021; 397(10280):1178-1181. PMC: 7993933. DOI: 10.1016/S0140-6736(21)00502-X. View

18.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

19.

Barros-Martins J, Hammerschmidt S, Cossmann A, Odak I, Stankov M, Ramos G . Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021; 27(9):1525-1529. PMC: 8440184. DOI: 10.1038/s41591-021-01449-9. View